Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Data Shows 'Majority' of Patients in Liver Cancer Extension Study Have Stable Disease

Premium

Alnylam Pharmaceuticals this week announced data from a phase I extension study of its RNAi-based liver cancer therapy ALN-VSP, which showed the drug could control disease for more than six months in the majority of patients treated.

The findings include a complete response from an endometrial cancer patient with multiple liver metastases.

The extension study enrolled patients from a previous phase I trial who achieved stable disease after four months or longer of ALN-VSP treatment. Main objectives included continued evaluation of safety and tolerability and assessment of disease response.

Alnylam previously announced that it would only advance ALN-VSP into phase II testing with a partner, and that it expected to forge such a deal this year (GSN 5/10/2012).

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.